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Abstract
Activating transcription factor 3 (ATF3), which is encoded by an adaptive-response gene induced by various stimuli, plays an
important role in the cardiovascular system. However, the effect of ATF3 on cardiac hypertrophy induced by a pathological
stimulus has not been determined. Here, we investigated the effects of ATF3 deficiency on cardiac hypertrophy using in
vitro and in vivo models. Aortic banding (AB) was performed to induce cardiac hypertrophy in mice. Cardiac hypertrophy
was estimated by echocardiographic and hemodynamic measurements and by pathological and molecular analysis. ATF3
deficiency promoted cardiac hypertrophy, dysfunction and fibrosis after 4 weeks of AB compared to the wild type (WT)
mice. Furthermore, enhanced activation of the MEK-ERK1/2 and JNK pathways was found in ATF3-knockout (KO) mice
compared to WT mice. In vitro studies performed in cultured neonatal mouse cardiomyocytes confirmed that ATF3
deficiency promotes cardiomyocyte hypertrophy induced by angiotensin II, which was associated with the amplification of
MEK-ERK1/2 and JNK signaling. Our results suggested that ATF3 plays a crucial role in the development of cardiac
hypertrophy via negative regulation of the MEK-ERK1/2 and JNK pathways.
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Introduction
Cardiac hypertrophy occurs in response to stresses, such as
pressure and volume overload, neurohormones and mutations in
genes encoding sarcomeric proteins [1]. It can provide mechanical
advantages that help maintaining normal ejection performance to
endure increased workload [2]. However, in the long term, cardiac
hypertrophy predisposes individuals to heart failure, arrhythmia
and sudden death [3]. Although a series of studies have illustrated
that signaling pathways, including mitogen activated protein
kinases (MAPKs), phosphatidylinositol 3-kinase (PI3K)/AKT
and calcineurin/nuclear factor of activated T cells (NFAT), play
important roles in hypertrophic responses [3], the mechanisms
that regulate these pathways have not been clearly elucidated.
Therapies for cardiac hypertrophy still primarily focus on
modulating hemodynamics; therefore, it is important to clarify
the mechanisms involved in cardiac hypertrophy and to discover
new antihypertrophic targets.
Activating transcription factor (ATF) 3 is a member of the
activating transcription factor/cAMP responsive element-binding
protein (ATF/CREB) family of transcription factors, which bind
to a consensus DNA sequence (TGACGTCA) and share a leucine
zipper (bZIP) element [4,5,6]. Members of this family bind to
specific DNA via the basic region in this domain, and form
homodimers or heterodimers with other bZIP-containing proteins
via the leucine zipper region [4,6]. ATF3 has a low expression
level in quiescent cells, but is increased under stress conditions,
such as injury, ischemia, ischemia/reperfusion or chemical toxin,
and is considered as an adaptive-response gene [5,7]. Signals
including cytokines, chemokines, growth factors/hormones or
DNA damage can induce ATF3 expression [5,7,8].
In the cardiovascular system, ATF3 expression is induced by
TNF-a and acute hypoxia in vascular endothelial cells [9,10]. A
variety of stimuli, including serum, angiotensin II (Ang II) and
H2O2, can increase the ATF3 expression in vascular smooth
muscle cells (VSMCs), and, knockdown of ATF3 induces VSMCs
apoptosis, caspase-3 cleavage and cytochrome c release [11]. In
addition, doxorubicin-treated neonatal rat cardiomyocytes have
high ATF3 expression via the JNK pathway, while ATF3
overexpression protects cardiomyocytes from doxorubicin-induced
apoptosis [12]. In vivo, the cardiac expression of ATF3 is induced
by ischemia/reperfusion [13] and Ang II [14], and transgenic
mice with cardiac-specific expression of ATF3 exhibit atrial
enlargement, atrial and ventricular hypertrophy, fibrosis, reduced
contractility and aberrant conduction[13]. However, the effect of
ATF3 deficiency on cardiac hypertrophy, especially, when
induced by pathological stimuli, has not been determined. For
this study, we used ATF3-knockout (KO) mice and cultured
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gate the role of ATF3 in the hypertrophic response. We show that
ATF3 deficiency in mice promotes cardiac hypertrophy, dysfunc-
tion and fibrosis in response to pressure overload, suggesting a
crucial role for ATF3 in modulating cardiac remodeling.
Materials and Methods
Animals and animal models
All animal procedures were performed in accordance with the
Guide for the Care and Use of Laboratory Animals published by the US
National Institutes of Health (NIH Publication No. 85-23, revised
1996) and approved by the Animal Care and Use Committee of
Renmin Hospital of Wuhan University (protocol number:
00013274). Male ATF3-KO mice (C57 background) and their
wild-type (WT) littermates aged 8 to 10 weeks were used in the
studies. The ATF3-KO mice were kindly provided by Dr.
Tsonwin Hai from Department of Molecular and Cellular
Biochemistry and Center for Molecular Neurobiology, Ohio State
University, Columbus, Ohio, USA. Genotyping was performed by
PCR as described previously [15]. Aortic banding (AB) was
performed as described previously [16,17]. Hearts and lungs of the
sacrificed mice were harvested and weighed to compare heart
weight/body weight (HW/BW, mg/g), lung weight/body weight
(LW/BW, mg/g), and heart weight/tibia length (HW/TL,
mg/mm) ratios in KO and WT mice.
Echocardiography and hemodynamics
Echocardiography was performed in anesthetized (1.5% isoflur-
ane) mice using a Mylab 30CV (ESAOTE S. P. A) with a 10-MHz
linear array ultrasound transducer. The left ventricle (LV)
dimensions were assessed in parasternal short-axis view. End-systole
or end-diastole was defined as the phase in which the smallest or
largest area of the LV was obtained, respectively.
For hemodynamic measurements, mice were anesthetized with
1.5% isoflurane, and a microtip catheter transducer (SPR-839,
Millar Instruments, Houston, TX, USA) was inserted into the right
carotid artery and advanced into the left ventricle. The signals were
continuously recorded using a Millar Pressure-Volume System
(MPVS-400, Millar Instruments, Houston, TX, USA), and the data
were processed by PVAN data analysis software.
Histological analysis and immunohistochemistry
Hearts were excised, washed with PBS, arrested in diastole with
10% KCl, weighed, fixed by perfusion with 10% formalin, and
embedded in paraffin. Hearts were cut transversely close to the
apex to visualize the left and right ventricles. Several sections of
each heart (4–5 mm thick) were prepared, stained with hematox-
ylin and eosin (H&E) for histopathology or picrosirius red (PSR)
for collagen deposition and then visualized by light microscopy.
For myocyte cross-sectional area, the sections were stained with
FITC-conjugated WGA (Invitrogen) to visualize membranes and
DAPI to visualize nuclei. A single myocyte was measured with a
quantitative digital image analysis system (Image Pro-Plus, version
6.0). The outline of 100 myocytes was traced in each group. For
immunohistochemistry, the heart sections were heated using the
pressure cooker method for antigen retrieval, incubated with anti-
ATF3 (Santa Cruz Biotechnology, sc-188) and subsequently an
anti-rabbit EnVisionTM+/HRP reagent, and stained using a
DAB detection kit.
Quantitative real-time RT-PCR
Real-time PCR was used to detect the mRNA expression levels of
hypertrophic and fibrotic markers. Total RNA was extracted from
frozen mouse cardiac tissue or cultured cardiac myocytes using
TRIzol (Invitrogen, 15596-026), and their yields and purities were
spectrophotometrically estimated using the A260/A280 and A230/
260 ratios via a SmartSpec Plus Spectrophotometer (Bio-Rad). The
RNA (2 mg of each sample) was reverse-transcribed into cDNA using
oligo (DT) primers and the Transcriptor FirstStrand cDNA Synthesis
Kit (Roche, 04896866001). The PCR amplifications were quantified
using a LightCycler 480 SYBR Green 1 Master Mix (Roche,
04707516001) and the results were normalized against glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) gene expression.
Western blotting
Cardiac tissue and cultured cardiac myocytes were lysed in
RIPA lysis buffer, and the protein concentration was measured
with the BCA protein assay kit (Themo, 23227) by ELISA
(Synergy HT, Bio-tek). The cell lysate (50 ug) was used for SDS/
PAGE, and the proteins were then transferred to Immobilon-FL
transfer membranes (Millipore, IPFL00010). The primary anti-
bodies included antibodies specific for p-MEK1/2 (Cell Signaling
Technology, 9154), T-MEK1/2 (Cell Signaling Technology,
9122), p-ERK1/2 (Cell Signaling Technology, 4370), T-ERK1/
2 (Cell Signaling Technology, 4695), p-P38 (Cell Signaling
Technology, 4511), T-P38 (Cell Signaling Technology, 9212),
p-JNK (Cell Signaling Technology, 4668), T-JNK (Cell Signaling
Technology, 9258), p-p90RSK(Cell Signaling Technology, 9335),
T-p90RSK (Cell Signaling Technology, 9347), p-AKT (Cell
Signaling Technology, 4060), T-AKT (Cell Signaling Technology,
4691), GAPDH (Cell Signaling Technology, 2118), and ATF3
(Santa Cruz Biotechnology, sc-188). The secondary antibody was
goat anti-rabbit (LI-COR, 926-32211) IgG. The blots were
scanned by a two-color infrared imaging system (Odyssey, LI-
COR). Specific protein expression levels were normalized to
GAPDH protein for total cell lysates and cytosolic proteins.
Neonatal mouse cardiomyocyte culture and surface area
Primary cultures of mouse ventricular cardiomyocytes were
prepared as described previously [18] with minor modifications.
Newborn (1–2-day old) WT and KO mice (C57 background) were
killed by swift decapitation, and the ventricles were minced and
digested in PBS (HyClone, SH30256.01B) containing 0.03%
trypsin (HyClone, SH30042.01) and 0.04% collagenase type II
(Sigma, C6885-1G). The harvested cells were centrifuged, and the
sediment was resuspended in Dulbecco’s modified Eagle’s medium
(DMEM)/F12 1:1 medium (HyClone, SH30023.01B) supplement-
ed with 20% fetal bovine serum (FBS; HyClone, SV30087.02),
100 U/ml penicillin/100 mg/ml streptomycin (Gibco, 15140) and
0.1 mmol/L bromodeoxyuridine (BrdU; Sigma, B5002). The
fibroblast content of the cell suspension was removed by a
differential attachment technique. Cell-rich medium was planted
to 35-mm dishes coated with gelatin. After 48 h, the culture
medium was changed to serum-free DMEM/F12 for 12 h before
the experiment, and then, the cultured myocytes were stimulated
with 1 mM Ang II (Sigma, A9525).
To identify the cardiomyocytes and assess cardiomyocyte
hypertrophy, we characterized cells by immunocytochemistry for
cardiac a-actinin. The cells were washed with PBS, fixed with
RCL2 (ALPHELYS, RCL2-CS24L), permeabilized in 0.1%
Triton X-100 in PBS, and stained with anti-a-actinin (Millipore,
05-384) at a dilution of 1:100 in 1% goat serum. The secondary
antibody was Alexa FluorH 568 goat anti-mouse IgG (Invitrogen,
A11004). The myocytes on coverslips were mounted onto glass
slides with SlowFade Gold antifade reagent with DAPI (Invitro-
gen, S36939).
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Samples of human failing hearts were collected from the left
ventricles of dilated cardiomyopathy (DCM) patients undergoing
heart transplants. Control Samples were obtained from the left
ventricles of the normal heart donors. The samples were obtained
with the approval of the local Ethical Committee (Renmin
Hospital of Wuhan University Human Research Ethics Commit-
tee, Wuhan, China). The investigation conformed to the principles
outlined in the Declaration of Helsinki. Informed written consent
was obtained from all subjects.
Statistical analysis
Data are expressed as the means 6 SEM. Differences among
the groups were determined by two-way ANOVA followed by a
post hoc Tukey test. Comparisons between the two groups were
performed by the unpaired Student’s t-test. P,0.05 was
considered to be significantly different.
Results
ATF3 expression in patients with dilated cardiomyopathy
and the pressure overload-induced hypertrophic mouse
model
We compared the cardiac expression of ATF3 in DCM patients
to that of healthy donators, and found that it was increased by 3.6-
fold (Figure 1A). Then we examined ATF3 expression in response
to pressure overload in mice. ATF3 expression Levels in the
murine heart were gradually elevated from 1 day to 4 weeks after
the AB operation (Figure 1B, C).
ATF3 deficiency promotes cardiac hypertrophy and
dysfunction in response to AB
To evaluate the effect of ATF3 on cardiac hypertrophy, we
performed the AB surgery or a sham operation on ATF3-KO
mice and WT littermates. After 4 weeks, echocardiography was
Figure 1. ATF3 expression in hypertrophic heart. A, Western blot analysis of cardiac expression of ATF3 in normal donators and in DCM
patients (n=4). *P,0.05 vs normal donators. B, Western blot analysis of cardiac ATF3 protein from WT mice after aortic banding at the time points
indicated (n=6). *P,0.05 vs sham. C, Immunohistochemistry of cardiac ATF3 protein from WT mice after aortic banding at time points indicated.
doi:10.1371/journal.pone.0026744.g001
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function of the left ventricle. There were no significant changes
between the sham-operated KO and WT mice; however, KO
mice exhibited deteriorated cardiac hypertrophy and dysfunction
compared to WT mice, as measured by LVEDD, LVESD,
interventricular septal thickness at end-diastole (IVSD), left
ventricular posterior wall thickness at end-diastole (LVPWD),
and fractional shortening (FS) after 4 weeks of AB (Figure 2A).
Pressure-volume (PV) loop analysis further revealed the exacer-
bated hemodynamic dysfunction of the LV in ATF3-KO mice, as
measured by parameters that reflect the volume, systolic function
and diastolic function of LV (Table 1). The HW/BW, HW/TL
and LW/BW ratios and the cardiomyocyte cross-sectional area
(CSA) were also strikingly increased in the pressure-overloaded
KO mice compared to the WT mice (Figure 2B). The gross
hearts, H&E staining and WGA staining confirmed the adverse
effect of ATF3 deficiency on cardiac remodeling (Figure 2C). In
addition, we used real-time PCR analysis to examine the mRNA
expression of markers of cardiac hypertrophy, including atrial
natriuretic peptide (ANP), B-type natriuretic peptide (BNP), b-
myosin heavy chain (b-MHC), a-myosin heavy chain (a-MHC)
and sarcoendoplasmic reticulum Ca
2+-ATPase (SERCA2a). AB-
induced up-regulation of cardiac fetal genes including ANP, BNP
and b-MHC were greater in ATF3-KO mice, which was
accompanied with the down-regulation of a-MHC and SER-
CA2a (Figure 2D). These results suggested that ATF3 deficiency
promotes cardiac hypertrophy and deteriorates impaired cardiac
function after pressure overload.
ATF3 deficiency augments myocyte hypertrophy in vitro
To further confirm the effect of ATF3 on cardiac hypertrophy,
we used an in vitro model with Ang II (1 mM) in cultured neonatal
mouse cardiomyocytes. After stimulation with Ang II, myocytes
from KO mice showed enlarged cell surface area compared to
those from WT mice (Figure 3A). Moreover, RT-PCR demon-
strated that ATF3 deficiency markedly enhanced the induction of
ANP and BNP mRNA expression by Ang II (Figure 3B). These
findings indicated that ATF3 deficiency promotes cardiac
hypertrophy in vitro.
Effects of ATF3 on MEK-ERK1/2 and JNK signaling
To examine the molecular mechanism by which ATF3 affects
the hypertrophic response, we investigated the activation of
MAPK in KO and WT heart induced by pressure overload.
Our data indicated that MEK-ERK1/2, JNK and p38 were
significantly activated in AB mice and that ATF3 deficiency
enhanced the phosphorylation of MEK-ERK1/2 and JNK.
However, we did not find an difference in phosphorylated p38
levels between KO and WT mice. Furthermore, we examined the
activation of 90-kDa ribosomal S6 kinase (p90RSK), a down-
stream effector of ERK1/2, and found that ATF3 deficiency
amplified the phosphorylation of p90RSK in response to AB. Akt
is another important signaling molecule involved in cardiac
hypertrophy, and our data showed that Akt activation was
increased in AB mice, although there was no striking difference
between the KO and WT group (Figure 4A, B). In vitro data
confirmed that the activation of MEK-ERK1/2, JNK and
p90RSK in myocytes from KO mice was greater compared to
WT mice in response to AngII (Figure 4C, D).
ATF3 deficiency exacerbates the fibrotic response
induced by pressure overload
Fibrosis is an important feature of developing pathological
cardiac hypertrophy. To detect fibrosis, heart sections were stained
with PSR. Striking perivascular and interstitial fibrosis was
observed in the WT mice in response to AB, and the extent of
cardiac fibrosis was remarkably increased in the KO mice
(Figure 5A, B). No significant difference in fibrosis was detected
between the WT and KO mice after the sham operation.
To further elucidate the effect of ATF3 on collagen synthesis,
we examined the mRNA expression of connective tissue growth
factor (CTGF), transforming growth factor (TGF)-b1, TGF-b2,
collagen I, collagen III, and fibronectin, which are responsible for
cardiac fibrosis. Our data showed that ATF3 deficiency enhanced
the increase of CTGF, TGF-b1, TGF-b2, collagen I, collagen III,
and fibronectin expression 4 weeks after AB (Figure 5C).
Discussion
Previous studies have proven that the ATF/CREB family plays
an important role in the cardiovascular system [11,12,13,14,19].
Figure 2. Effects of ATF3 on cardiac hypertrophy. A, Echocardiography results from 4 group mice at 4 weeks after AB or sham surgery (n=8).
B, Statistical results of the HW/BW, LW/BW, HW/TL and myocyte cross-sectional areas of indicated groups. C, Gross hearts, HE staining and WGA-FITC
staining of sham and AB mice at 4 weeks post surgery. D, Expression of transcripts for ANP, BNP, b-MHC, a-MHC and SERCA2a induced by AB were
determined by RT-PCR analysis (n=6). *P,0.05 vs WT/sham. # P,0.05 vs WT/AB after AB.
doi:10.1371/journal.pone.0026744.g002
Table 1. Hemodynamic parameters in mice after 4 weeks of
surgery.
Parameter Sham AB
WT(n=6) KO(n=6) WT(n=6) KO(n=6)
P–V loop analysis
HR (min
21) 47968 460684 6 1 611 460610
ESP (mmHg) 108.262.3 110.862.5 152.764.9* 155.467.8*
EDP (mmHg) 10.960.6 11.660.9 17.962.3 25.462.9*
ESV (ml) 10.260.5 11.360.4 21.660.9* 29.262.2#
EDV (ml) 2760.7 26.8613 4 . 2 60.6* 37.961.7#
Systolic function
dP/dt max (mmHg/s) 102796415 99426538 81076265* 66646567#
Ea (mmHg/ml) 5.660.1 6.460.4 10.860.8* 14.660.9#
EF(%) 66.761.2 61.861.5 41.362.7* 27.961.7#
CO (ml/min) 93566211 81576438 66556398* 49576224#
Stroke volume (ml) 19.560.3 17.861.0 14.561.0* 10.860.4*
Diastolic function
dP/dt min (mmHg/s) 293406422 293086286 278746419* 256986519#
Tau_w(ms) 7.460.2 7.460.4 9.260.4 12.361.4#
HR, heart rate; ESP, end-systolic pressure; EDP, end-diastolic pressure; ESV, end-
systolic volume; EDV, end-diastolic volume; Ea, arterial elastance; EF, ejection
fraction; CO, cardiac output; dp/dtmax, maximal rate of pressure development;
dp/dtmin, maximal rate of pressure decay; Tau_w, time constant of isovolumic
pressure decay.
*P,0.05 vs WT/sham.
#P,0.05 vs WT/AB after AB.
doi:10.1371/journal.pone.0026744.t001
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cardiac hypertrophy induced by pressure overload in vivo and by
Ang II in vitro. The effects of ATF3 on cardiac hypertrophy,
dysfunction and fibrosis are probably mediated by negative
feedback to the ERK and JNK pathways and regulation of pro-
fibrotic cytokines. These results suggest that ATF3 may play a
protective role in pathological hypertrophy in the heart and may
be an effective therapeutic target for cardiac hypertrophy and
heart failure.
ATF3, a member of the ATF/CREB family, contains the
bZIP element and plays a role as either a repressor or activator
of transcription via forming homodimers or heterodimers with
other bZIP-containing proteins such as ATF2 and c-Jun [4].
ATF3 is an adaptive-response gene and is induced by various
environmental stresses, including injury, ischemia, ischemia/
reperfusion, chemical toxin, cytokines, chemokines, and growth
factors/hormones [5,7,8]. Previous studies have shown increased
ATF3 expression in mice injected with Ang II, isoproterenol or
phenylephrine [14,20]. We demonstrated that high ATF3
expression was not only in response to aortic banding in mice
but also in the hearts of patients with DCM, which suggests that
ATF3 is involved in the development of cardiac hypertrophy.
Mice with cardiac-specific over-expression of ATF3 exhibited
atrial enlargement and cardiac hypertrophy in a previous report
[13]; however, our results demonstrated that ATF3 deficiency
promotes pathological hypertrophy. It seems obscure that the
role of ATF3 in cardiac hypertrophy is whether detrimental or
protective. The first possibility for the discrepancy is that the
transgenic mice have a persistent expression of ATF3. Previous
study showed that adenovirus-mediated expression of ATF3
could inhibit doxorubicin-induced cardiomyocytes apoptosis
[12], which indicated that transient expression of ATF3 may
be protective on cardiomyocytes. Loss of ATF3 may impair the
resistant ability of heart under stress. Secondly, the expression
level of ATF3 in the transgenic mice may be too high for the
homeostasis. Thirdly, ATF3 have dual roles in the regulation of
transcription: as either a repressor or activator [4]. Therefore, it
is likely that ATF3 is necessary in the defense against
pathological stress in the heart, and its up-regulation may be
protective in the progression of cardiac hypertrophy. However,
persistent overexpressed ATF3 may play as a transcriptional
activator rather than repressor of pro-hypertrophic genes, which
is detrimental to the heart, indicating that it is important to
regulate the level and duration of ATF3 expression to resist
hypertrophic stress.
Fibrosis, which is an integral feature of cardiac remodeling, is a
disproportionate accumulation of fibrillar collagen leading to
expansion of the extracellular matrix (ECM) and cardiac
dysfunction [21]. Myocardial fibrosis following pressure overload
is associated with increased accumulation of type I and III
collagen within the adventitia of coronary arteries (perivascular
fibrosis), which progressively extends into the neighboring
interstitial spaces (interstitial fibrosis) [22]. We found enhanced
deposition of collagen in ATF3-KO mice after AB and
demonstrated that ATF3 deficiency promotes collagen synthesis,
with up-regulated mRNA levels of collagen I and III. TGFb and
CTGF are two major extracellular signals that promote fibrosis in
the hypertrophic heart [23,24], and our study showed increased
mRNA expression of these cytokines in ATF3-KO mice after AB.
These results suggest that ATF3 could protect against cardiac
remodeling through regulation of pro-fibrotic cytokines and
collagen content.
The molecular mechanisms by which ATF3 affects cardiac
remodeling remain unclear. Recent evidence has suggested that
the MAPK cascade is involved in cardiac hypertrophy and
fibrosis [25,26]. The MAPK cascade is initiated in cardiac
myocytes by various stress stimuli. After activation, downstream
p38, JNKs, and ERKs each phosphorylate a wide array of
Figure 3. ATF3 deficiency augments myocyte hypertrophy in vitro. A, Effect of ATF3 deficiency on the enlargement of myocyte induced by
Ang II (1 mM for 48 h). B, RT-PCR analysis of the mRNA levels of ANP and BNP induced by Ang II at the time points indicated. *P,0.05 vs WT group at
the 0 time point. # P,0.05 vs WT group at the same time point.
doi:10.1371/journal.pone.0026744.g003
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resulting in the reprogramming of cardiac gene expression [27].
ATF3 expression is also regulated by the MAPK cascades
[28,29]. ERK pathway is necessary in serum-induced ATF3
expression, which was evidenced by that the specific MEK1
kinase inhibitor PD98059 almost completely abolished the serum
induction of ATF3 by suppressing the phosphorylation of ERK
[30]. And, the activation of the ERK is essential for ATF3
induction in the left atrium following acute angiotensin II
stimulation [14]. JNK pathway is involved in the induction of
ATF3 by acute hypoxia and homocysteine in endothelial cells,
which was confirmed by using specific inhibitor or expressing
dominant negative upstream moleculars of JNK [10,31].
Furthermore, ATF3 is also activated by JNK in doxorubicin-
treated neonatal rat cardiomyocytes [12]. On the other hand,
ATF3 could suppress tumorigenesis stimulated by Ras [32]
which is upstream of MEK-ERK1/2 and JNK, and prevent
JNK-induced neuronal death [33]. Results of these studies
indicated the interaction between ATF3 and MEK-ERK1/2 and
JNK. In our study, we found that pressure overload induced the
activation of ERK1/2, JNK and p38, as well as MEK1/2, the
upstream activator of ERK1/2. We then demonstrated that
ATF3 deficiency enhanced the increased phosphorylation of
MEK-ERK1/2 and JNK after AB but did not affect p38
phosphorylation. P90RSK, a downstream effector of ERK1/2,
regulates a number of transcription factors and interacts with
other kinases involved in hypertrophic response [34,35]. Our
results showed that ATF3 deficiency increased the phosphory-
lation of p90RSK in response to AB. Akt is another pathway that
play crucial role in cardiac hypertrophy [36]. A recent study
reported that ATF3 affected mast cells development and function
via the Akt pathway [37]; however, we did not detect the
influence of ATF3 on Akt phosphorylation. Previous studies have
described ATF3 as a ‘‘hub’’ of the cellular adaptive-response
network [8], indicating the complex role of ATF3 in diseases.
Our results demonstrated that ATF3 provides negative feedback
to the ERK and JNK pathways to modulate cardiac remodeling,
providing more clues into the functional network of ATF3.
Figure 4. Effects of ATF3 on the ERK and JNK signaling pathways. (A and B) The levels of total and phosphorylated MEK1/2, ERK1/2, JNK, P38,
P90RSK and AKT in the heart tissues of mice in the indicated groups (n=6). A, Representative blots. B, Quantitative results. *P,0.05 vs WT/sham.
# P,0.05 vs WT/AB after AB. (C and D) The levels of total and phosphorylated MEK1/2, ERK1/2, JNK and p90RSK in cardiac myocytes treated with
Ang II at the indicated time points. C, Representative blots. D, Quantitative results. *P,0.05 vs WT group at the 0 time point. # P,0.05 vs WT group
at the same time point.
doi:10.1371/journal.pone.0026744.g004
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mechanism by which ATF3 regulates ERK and JNK pathways.
In conclusion, this study reveals a previously unknown effect of
ATF3 on cardiac hypertrophy, dysfunction and fibrosis in
response to hypertrophic stimuli by the negative feedback to
the ERK and JNK pathways and regulation of pro-fibrotic
cytokines and collagen content. Our study provides new insight
into the pathogenesis of cardiac remodeling and may have
important implications for the development of strategies for the
treatment of cardiac hypertrophy and heart failure through
targeting ATF3.
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